Clin Cancer Res: JWCAR029 is effective and safe for treating incurable B-NHL.

Anti-CD19 inlay antigen-treated (CAR) T-cells are a novel immunotherapy that is very effective in treating relapsed/refractic B-cell non-Hodgkin's lymphoma (B-NHL).
the clinical response of cancer micro-environments to CAR T treatment remains a very interesting issue.
phase I, first human case, dose incremental study of anti-CD19 JWCAR029 in refrectable B-NHL (NCT03355859), and 10 patients received 2.5× an incremental dose of CAR T cells for cells 107 (n s 3), 5×107 (n s 4) and 1×108 (n s 3).
When sufficient CAR T cell amplification is detected, a fine needle biopsy is performed on patients with diffuse large B-cell lymphoma on day-6 (1 day before lymphatic clean-up) and 11 days after CAR T cell infusion.
results showed a total response rate of 100 per cent, with 6 out of 9 assessable patients (66.7 per cent) in complete remission.
most common adverse events above level 3 are neutral granulocyte reduction (10/10,100%), anemia (3/10,30%), plateplate reduction (3/10,30%) and hypofibroteinogenemia (2/10,20%).
all patients had stage 1 cytokine release syndrome and 1 patient had stage 3 neurotoxicity.
at three different dose levels, the average peak levels of exostose CAR T cells and cytokines were similar, but there was a significant increase in CAR T cells in patients who reached full remission on the 29th day.
, RNA sequencing identified gene expression characteristics that completely alleviated and partially alleviated differential abundance in patients.
tumor-related macrophage immersion was negatively associated with the remission state.
, the results show that JWCAR029 treatment of responsive B-NHL is effective and safe.
the composition of the tumor micro-environment has a potential effect on the treatment response of CAR T.
.